Revenue
Margin
Demand
Guidance
Tone
Sagility Limited - Q1 FY27 Earnings Call Summary Tuesday, July 21, 2026 7:30 PM
Event Participants
Executives
2
Ramesh Gopalan, Srinivas Mattapalli
Analysts
9
Akshat Agarwal, Arvind Arora, Baidik Sarkar, Rishabh Mehra, Rishi Jhunjhunwala, Rohit Thorat, Sameer Pardikar, Seema Nayak, Vamshi Krishna
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹19,635 million ($207.8 million) | +27.6% YoY; +15.2% constant currency. Organic ex-CareSeed +27.3% in INR / +14.9% CC. Q1 includes ~3 weeks of CareSeed revenue (acquisition closed June 11, 2026). |
| Sequential steady-state growth | 5.1% QoQ CC (organic) | Reported revenue declined QoQ due to ~$24.8 million of non-recurring Q4 FY26 OE/AEP revenue; steady-state revenue grew from $197.3 million to $207.3 million. |
| Adjusted EBITDA | ₹4,716 million ($49.9 million) | +27.9% YoY; margin 24.0% vs 24.9% in Q4 FY26. Absorbed ~40bps minimum-wage impact, ~50bps annual salary increases, and ~100bps seasonal de-leverage, offset by >100bps FX gains. |
| Adjusted PAT | ₹2,697 million ($28.6 million) | +35.1% YoY; margin 13.7%; aided by strong operations and lower finance costs. |
| New deal ACV | $35.3 million steady-state | Signed across 18 existing clients and 1 new logo in Q1. |
| Headcount & attrition | 47,307 employees; 28.6% quarterly voluntary attrition | Improved from 38.1% in Q4 FY26; marginally higher than Q1 FY26. |
| Revenue mix & clients | Payers 89.6% / Providers 10.4%; 109 active client groups | 26 net new client groups added via CareSeed, each currently <$1 million revenue. |
| DSO | 80 days | Improved from 87 days in Q4 FY26 (52 days receivables + 28 days unbilled). |
| Operating cash flow | ₹3,161 million | ~70% EBITDA-to-cash conversion; free cash flow ₹2,416 million after ₹745 million capex; ₹1,360 million paid for M&A. |
| Cash & net debt | Cash ₹9,674 million; net debt ₹1,110 million | Net debt-to-adjusted EBITDA at 0.06x; on track to fully repay debt during FY27. |
| Adjusted ROCE | >50% | Efficient capital deployment; adjusted EPS growing faster than revenue. |
Geographic & Segment Commentary
- Payers (89.6% of revenue): Growth led by expansion within existing client relationships, with FY26 client additions scaling and sustained demand across higher-value service lines including clinical. U.S. payers prioritise margin recovery, care management effectiveness, stars performance, and administrative cost reduction amid rising medical costs, regulatory complexity, and membership volatility.
- Providers (10.4% of revenue): Management continues to evaluate provider-side/RCM M&A but notes targets have carried high valuations with limited capability accretion; approach remains selective.
- Mid- and small-payer segment: CareSeed adds 26 clients (each <$1 million revenue) and a HEDIS/quality platform; BroadPath cross-sell pipeline has 6-7 active conversations. CareSeed's technology is mid-market-oriented, but packaging platform-plus-services could open large-client opportunities.
- Seasonal OE/AEP operations: FY25 seasonality was
$20 million (3% of revenue); FY26 rose to$50 million (6%) driven by BroadPath and new seasonal clinical work. Similar ~6% intensity expected in FY27; Q1 sequential decline is structural seasonality, not demand weakness.
Company-Specific & Strategic Commentary
- CareSeed acquisition: Closed June 2026; CY25 revenue $5.1 million with 95% recurring revenue and 31.4% EBITDA margin; 14-member team. Adds Forecast (HEDIS reporting/quality analytics) and Harvest (cloud-based chart abstraction) platforms; combined with Sagility's population health/AIP platform, creates an end-to-end quality operations continuum from care-gap identification to closure, supporting Medicare Advantage stars improvement and revenue uplift.
- Managed services & Sagility Synchrony: Traction building with managed-service constructs where Sagility takes operational ownership and outcome accountability at lower cost. Sagility Synchrony (AI-led orchestration platform) connects fragmented claims/adjustment workflows for faster decisions. Everest Group research across 50 payers: 70% adopted AI but only 10% reported measurable improvement; 70% prioritise domain-led intelligent operations — validating Sagility's workflow-redesign-first approach.
- AI-led deflation: Historical annual revenue deflation of 100-150bps from onshore-to-offshore migration, automation, and AI; could rise to ~200bps. Not tracked quarterly; broader update planned next quarter. No pricing levers exist — client pricing pressure runs in the opposite direction.
- Talent & recognition: Ranked 11th in Great Place to Work India 2026 (first year of participation); ET Edge recognition for women; named major contender in Healthcare CXM and RCM PEAK Matrix 2026; Avasant leader in clinical and care management business process transformation.
- Deleveraging & capital allocation: Net debt reduced to ₹1,110 million (0.06x EBITDA) with ₹9,674 million cash; full debt repayment targeted during FY27, further reducing finance costs; prudent capital allocation balancing growth investments and balance sheet flexibility.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 organic revenue growth | Low double-digit in constant currency (reiterated) | Broad-based growth across existing clients and scaling FY26 additions; managed-service deal timing is the key uncertainty. Better visibility post-Q2 once OE/AEP season pans out. |
| FY27 adjusted EBITDA margin | 24% to 25% (maintained) | Absorbs ~120bps incremental Karnataka/Telangana minimum-wage impact plus annual salary hikes; supported by FX depreciation and operational efficiency. If wage impact is lower than estimated, could exit the upper end or higher. |
| Debt repayment | Full repayment during FY27 | Will further strengthen balance sheet and reduce finance costs. |
| FY27 seasonal revenue | ~6% of revenue, similar to FY26 | OE/AEP volumes are recurring; proportion expected to hold, though client-specific volumes known only by September. |
| Margin precision | Narrower range after Q2 | Management expects to beat the lower end of 24-25%; full-quarter minimum-wage impact and OE visibility will drive refinement on the next call. |
Risks & Constraints
| Risk | Context |
|---|---|
| Minimum wage inflation | Karnataka/Telangana statutory revisions (effective May 2026) drive ~120bps FY27 adjusted EBITDA impact (₹70 million in Q1) plus a ₹151 million one-time past-service cost booked as exceptional. ~65-70% of headcount is in Bangalore/Hyderabad; mitigation via geographic expansion and operational efficiency, fully realised over 12-18 months. |
| Pricing pressure & AI-led deflation | Clients facing margin pressure expect AI-driven cost takeout; annual revenue deflation of 100-150bps could rise to ~200bps. No pricing lever; offset via productivity gains and FX. Everest data shows most payers have not yet realised AI gains, keeping cost expectations high. |
| Seasonality & deal timing | ~6% of revenue is concentrated in Q3/Q4 OE/AEP, causing structural Q1 sequential declines. Large managed-service deals take 3-6+ months of conversations, making quarterly timing unpredictable. |
| Client concentration & migration | Top 4/5 client cohort TTM growth is temporarily soft as one client migrates a large volume onshore-to-offshore; directionally margin-accretive but near-term revenue-dilutive. |
| M&A availability & valuation | Provider/RCM acquisition targets have been expensive with limited capability accretion; pipeline focused on clinical services, provider-side capabilities, and healthcare technology. |
| FX & hedging | Rupee depreciation supports adjusted EBITDA ( >100bps in Q1), but hedges taken at lower rates will pressure reported EBITDA/EPS; reported vs adjusted divergence possible. |
Q&A Highlights
Minimum Wage Exposure, Recurrence and Mitigation
- Question: What proportion of employees are on statutory minimum wage in Karnataka/Telangana? Is the 120bps impact recurring and recoverable? (Akshat Agarwal, Jefferies)
- Answer: Less than 15-20% of employees are outside Karnataka/Telangana; ~65-70% of headcount is in Bangalore and Hyderabad, with cascading pay-parity effects beyond base-level associates (Srinivas Mattapalli). The impact is recurring for FY27; mitigation through expansion in unaffected states and accelerated operational efficiency, with full benefit playing out over 12-18 months (Ramesh Gopalan).
Growth Composition and Guidance Conservation
- Question: Can the ~15% CC growth be split between existing and FY26 clients? Was pricing a lever? Why guide low double-digit after 5.1% sequential? (Baidik Sarkar, Unifi Capital)
- Answer: No pricing levers were exercised — client pricing pressure runs in the opposite direction. Growth is broad-based; top clients are increasing and buying additional services, and FY26 client additions are scaling. Delivery capacity is not the constraint; managed-service deal timing is. The mix includes both outcome-based deals and process-level FTE/transaction-rate work (Ramesh Gopalan).
Top Client Cohort Softness
- Question: Why is TTM growth in the top 4/5 client cohort soft relative to other cohorts? (Rohit Thorat, Axis Capital)
- Answer: One client in that cohort is actively migrating a large volume from onshore to offshore, temporarily reducing revenue; this onshore-to-offshore shift is a recurring pattern as clients move work offshore over time (Ramesh Gopalan).
Margin Path and Full-Quarter Wage Impact
- Question: With Q1 already at 24% and no further headwinds, why not raise the lower end of the 24-25% guidance? (Rohit Thorat, Axis Capital)
- Answer: Q1 absorbed only a partial minimum-wage impact (Karnataka effective May 23); the full-quarter Q2 impact will be more than double Q1's. FX hedges taken at lower rates will also pressure reported EBITDA/EPS. Management expects to do better than the lower end; a narrower range will be provided post-Q2 (Ramesh Gopalan). A follow-up confirmed the offset is a combination of rupee depreciation and planned operational efficiency initiatives (Ramesh Gopalan, to Rishi Jhunjhunwala, IIFL Capital).
M&A Pipeline and Mid-Market Cross-Sell
- Question: Which areas for the next acquisition? How is cross-sell progressing at BroadPath and CareSeed? (Vamshi Krishna, Kotak Securities)
- Answer: Interest areas are clinical services, provider-side capabilities, and healthcare technology; many RCM targets were expensive without capability accretion. BroadPath has 6-7 active cross-sell conversations. CareSeed's technology is mid-market-focused, but packaging platform plus services could open large-client care management opportunities (Ramesh Gopalan).
Payer Spending and Top-10 Insurer Penetration
- Question: Is US payer spending tightening? What is required to penetrate the remaining top-10 national payers? (Rishi Jhunjhunwala, IIFL Capital)
- Answer: No general slowdown seen in core operations; clients remain focused on cost takeout, and a strong value proposition still wins. Sagility is present in 7 of the top 10 payers; entry into the remaining three will come through clinical and payment integrity services — areas not traditionally outsourced to the same extent as claims and enrolment (Ramesh Gopalan).
Seasonal Revenue Recurrence and BroadPath Contribution
- Question: Is FY26's ~$50 million seasonal revenue sustainable? Can you provide BroadPath's revenue share? (Sameer Pardikar, Elara Capital; Seema Nayak, ICICI Securities)
- Answer: FY25 seasonality was
$20 million (3% of revenue); FY26 rose to$50 million (6%) due to BroadPath plus new seasonal clinical work; a similar ~6% is expected for FY27. BroadPath contributed ~$13.5-13.6 million in Q1 FY27. OE-specific volume details will only be known by September, when plans finalise bids (Srinivas Mattapalli; Ramesh Gopalan).
Insourcing Risk and Client AI Expectations
- Question: Any risk of clients insourcing as margins tighten? Are clients pressing for AI-led price deflation? (Rishabh Mehra, Demeter Advisors)
- Answer: Insourcing offshore work would increase client costs, so it is unlikely under cost pressure. Clients expect AI to reduce operating costs, but Everest research shows only 10% achieved measurable gains. Sagility's proposition is end-to-end workflow redesign with committed cost takeout, aligned with client objectives. The proposed 3% ESOP pool is still in approval; impact will be reported once grants are made (Ramesh Gopalan; Srinivas Mattapalli).
Key Takeaway
Sagility opened FY27 with revenue of ₹19,635 million ($207.8 million), up 27.6% YoY (14.9% organic constant-currency), and adjusted EBITDA of ₹4,716 million (24.0% margin) despite absorbing annual salary increases, 40bps of minimum-wage impact, and seasonal de-leverage — offset largely by FX gains. Adjusted PAT rose 35.1% to ₹2,697 million. New wins of $35.3 million ACV and 28.6% attrition underscored commercial and talent momentum. Management reiterated FY27 guidance of low double-digit organic CC growth and 24-25% adjusted EBITDA margins, absorbing the ~120bps Karnataka/Telangana minimum-wage headwind via geographic expansion and efficiency, with full mitigation over 12-18 months. The CareSeed acquisition (26 new mid/small-payer clients, HEDIS/quality platforms) extends the quality continuum and cross-sell runway. Watch items: full Q2 minimum-wage impact, OE/AEP seasonality (6% of revenue) visibility by September, and AI-led deflation of 100-200bps.